What is the characteristic of dishonest behavior in children ages 8 to 10 years?

The correct answer is choice B: Pulmonic stenosis, ventricular septal defect, overriding aorta, right ventricular hypertrophy.

Choice A rationale:

Pulmonic stenosis, ventricular septal defect, aortic hypertrophy, left ventricular hypertrophy. This choice is incorrect because it includes "aortic hypertrophy" and "left ventricular hypertrophy," which are not components of the tetralogy of Fallot. Aortic hypertrophy is not a recognized structural defect in tetralogy of Fallot, and left ventricular hypertrophy is not a characteristic feature of this congenital heart condition.

Choice B rationale:

Pulmonic stenosis, ventricular septal defect, overriding aorta, right ventricular hypertrophy. This is the correct choice. Tetralogy of Fallot is characterized by four specific structural defects: pulmonic stenosis (narrowing of the pulmonary valve), ventricular septal defect (hole between the right and left ventricles), overriding aorta (aorta positioned over the ventricular septal defect, receiving blood from both ventricles), and right ventricular hypertrophy (enlargement of the right ventricle due to increased workload).

Choice C rationale:

Aortic stenosis, ventricular septal defect, overriding aorta, right ventricular hypertrophy. This choice is incorrect because it includes "aortic stenosis," which is not part of the tetralogy of Fallot. In tetralogy of Fallot, the stenosis occurs at the pulmonary valve, not the aortic valve.

Choice D rationale:

Aortic stenosis, atrial septal defect, overriding aorta, left ventricular hypertrophy. This choice is incorrect. While "overriding aorta" is present in tetralogy of Fallot, "atrial septal defect" and "left ventricular hypertrophy" are not part of this condition. Atrial septal defects involve a hole between the two atria, not the ventricles, and left ventricular hypertrophy is not typically seen in tetralogy of Fallot.

Choice A rationale:

Calcium carbonate is often given with meals to individuals with chronic renal disease, especially those on dialysis. One of the primary purposes is to bind dietary phosphorus in the gastrointestinal tract. In chronic renal disease, the kidneys are less effective at filtering out excess phosphorus from the blood, leading to elevated phosphorus levels (hyperphosphatemia). Elevated phosphorus levels can contribute to bone and mineral disorders in these patients. Calcium carbonate forms insoluble calcium phosphate complexes with dietary phosphorus, preventing its absorption and facilitating its elimination from the body through the feces.

Choice B rationale:

While calcium carbonate can interact with fat-soluble vitamins like vitamin D, the primary reason for administering it to individuals with chronic renal disease is to manage phosphorus levels. Calcium carbonate can bind phosphorus and prevent its absorption, which is particularly important for patients with compromised kidney function.

Choice C rationale:

Stimulating appetite is not a primary purpose of administering calcium carbonate to children with chronic renal disease. The main focus is on managing phosphorus levels and preventing complications associated with hyperphosphatemia.

Choice D rationale:

Preventing vomiting is not a primary purpose of giving calcium carbonate to children with chronic renal disease. Calcium carbonate is typically used to manage phosphorus levels and complications related to hyperphosphatemia in this population.